|
Oct 1
|
Update: Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
|
|
Oct 1
|
Market Chatter: Sanofi Asks Bidders to Revise Offers for Consumer Health Unit
|
|
Oct 1
|
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
|
|
Sep 30
|
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
|
|
Sep 28
|
Regeneron, Sanofi announce Dupixent approval in China for patients with COPD
|
|
Sep 27
|
Regeneron-Sanofi Drug Wins FDA Approval To Treat COPD
|
|
Sep 27
|
Sanofi/Regeneron’s Dupixent set to dominate COPD biologics market following FDA approval
|
|
Sep 27
|
Regeneron, Sanofi Get FDA OK for Dupixent to Treat COPD
|
|
Sep 27
|
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
|
|
Sep 27
|
Dupixent® (dupilumab) Approved in the U.S. as the First-ever Biologic Medicine for Patients with COPD
|
|
Sep 27
|
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
|
|
Sep 27
|
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
|
|
Sep 27
|
Dupixent® (dupilumab) Approved in China as the First-ever Biologic Medicine for Patients with Chronic Obstructive Pulmonary Disease (COPD)
|
|
Sep 27
|
FDA, after delay, clears Regeneron and Sanofi drug for COPD
|
|
Sep 26
|
Are Investors Undervaluing Sanofi (SNY) Right Now?
|
|
Sep 26
|
Buy These 5 Big Drug Stocks to Boost Your Portfolio's Health
|
|
Sep 26
|
Press Release: Availability of the Q3 2024 Aide mémoire
|
|
Sep 25
|
Amgen Stock Falls on Disappointing Drug Data
|
|
Sep 25
|
Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff
|
|
Sep 25
|
Sanofi Gets Binding Bids from CD&R, PAI for Consumer Arm
|